This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Amedisys Ties Up With Medalogix to Boost Home Health Unit
by Zacks Equity Research
Amedisys (AMED) pursues deals to boost Home Health business.
Here's Why You Should Invest in Veeva (VEEV) Stock Right Now
by Zacks Equity Research
Strong fundamentals and a solid Q2 aid Veeva (VEEV).
Illumina MiSeq Dx Okayed in China, NGS Platform Gets a Boost
by Zacks Equity Research
Illumina's (ILMN) receipt of CNDA approval for MiSeq Dx Sequencing System is expected to expand customer base and boost the top line.
Here's Why You Should Invest in Phibro (PAHC) Right Now
by Zacks Equity Research
Phibro (PAHC) sees improvement across all segments. The Animal Health business has been a key contributor.
Here's Why You Should Buy Inogen (INGN) Stock Right Now
by Zacks Equity Research
Inogen (INGN) gains from strong Q2 results and bright global prospects.
Here's Why You Should Invest in Genomic Health (GHDX) Now
by Zacks Equity Research
Genomic Health (GHDX) gains ground on growing adoption of prostate cancer test and solid international scenario.
Ecolab's Nalco Pairs With XOS to Boost Global Energy Unit
by Zacks Equity Research
Ecolab's (ECL) Nalco Champion's 3D CRUDEFLEX will integrate XOS' Clora Online; market prospects bright.
New Buyouts Aid Boston Scientific Amid Dull Pacemaker Sales
by Zacks Equity Research
Boston Scientific (BSX) continues to adopt organic as well as inorganic routes for success. However, sluggish global pacemaker sales continue to disappoint.
Wright Medical Buys Cartiva to Boost Lower Extremities Unit
by Zacks Equity Research
Wright Medical's (WMGI) addition of Synthetic Cartilage Implant is likely to drive revenues in 2019; raised guidance for 2018 encourages.
STERIS (STE) Strategic Growth Strong, Competition a Woe
by Zacks Equity Research
STERIS' (STE) beneficial underlying market trends along with new product and service offerings are impressive. Meanwhile, the company worries over facing a severe competition.
Bruker to Expand Molecular Diagnostics Arm With Hain Buyout
by Zacks Equity Research
Hain's molecular diagnostics solutions of bacterial and viral infections are expected to compliment Bruker's (BRKR) MALDI Biotyper and IR Biotyper microbiology platforms.
Omnicell Patient Engagement Unit to Aid Medication Adherence
by Zacks Equity Research
Omnicell's (OMCL) revamped Patient Engagement platform likely to aid core Medication Adherence Unit; market looks promising.
Tap the Sleep Apnea Devices Market Boom With These 3 Stocks
by Sweta Jaiswal
Consider these three stocks in the sleep apnea devices market for grand returns.
Hill-Rom (HRC) Touches 52-Week High: What's Driving It?
by Zacks Equity Research
Hill-Rom (HRC) rides high on impressive Q3 results along with increased focus on product innovation through research and development.
Here's Why You Should Invest in Illumina (ILMN) Stock Now
by Zacks Equity Research
Illumina (ILMN) gains on strategic partnerships and international prospects.
Ecolab's New Aquanomic Enhances Laundry Operations at Hotels
by Zacks Equity Research
Ecolab's (ECL) new Aquanomic 2.0 Low-Temp Solid Laundry Program likely to boost Global Institutional segment.
Neogen's (NEOG) Listeria Right Now Gets Approval from AOAC
by Zacks Equity Research
Neogen's (NEOG) Listeria Right Now likely to prove beneficial in preventing food-borne diseases in the United States.
Masimo (MASI) Scales a 52-Week High: What's Driving It?
by Zacks Equity Research
Masimo's (MASI) solid guidance for 2018 and a broad product spectrum drive stock.
Here's Why You Should Add Amedisys (AMED) to Your Portfolio
by Zacks Equity Research
Amedisys (AMED) witnesses solid Medicare and non-Medicare revenues at Home Health and Hospice divisions. A favorable demographic trend bodes well.
Becton, Dickinson Hits at a 52-Week High: What's Driving It?
by Zacks Equity Research
Becton, Dickinson (BDX) gains on solid fiscal Q3 results; view impressive.
AngioDynamics' (ANGO) BioSentry Buyout to Boost Oncology
by Zacks Equity Research
AngioDynamics' (ANGO) latest buyout to bolster its core Oncology unit; market prospects look bright.
Wright Medical Strong Overseas, Back Order Issues Persist
by Zacks Equity Research
Wright Medical (WMGI) rides on recent approval of AUGMENT Injectable and a solid guidance for 2018; pricing pressure prevails.
Masimo's SET Pulse Oximetry Detects Sleep Apnea in Children
by Zacks Equity Research
Masimo's (MASI) SET pulse oximetry successfully identifies DS in children with high risk of OSA.
Masimo (MASI) Beats on Q2 Earnings, Raises 2018 Guidance
by Zacks Equity Research
Masimo (MASI) gains from solid segmental performance in Q2; non-invasive technology continues to be in demand.
Masimo (MASI) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Masimo (MASI) delivered earnings and revenue surprises of 1.39% and 1.74%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?